Glaukos (GKOS) announced positive three-year Phase 3 extension data for Epioxa, its epi-on corneal cross-linking therapy for keratoconus. Treated eyes showed sustained 1.9 D improvement in corneal curvature, with 29% gaining two or more lines of visual acuity. No serious adverse events were reported. The results reinforce Epioxa's long-term durability and safety profile.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
